Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US

2017 ◽  
Vol 86 ◽  
pp. 46-58 ◽  
Author(s):  
Marios K. Georgakis ◽  
Paraskevi Panagopoulou ◽  
Paraskevi Papathoma ◽  
Athanasios Tragiannidis ◽  
Anton Ryzhov ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Young Adults ◽  
Eastern Europe ◽  
Incidence Rates ◽  
Adolescents And Young Adults ◽  
Central Nervous System Tumours ◽  
The Us

scholarly journals An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008–2013

2019 ◽  
Vol 22 (6) ◽  
pp. 851-863 ◽  
Author(s):  
Sam Ng ◽  
Sonia Zouaoui ◽  
Faiza Bessaoud ◽  
Valérie Rigau ◽  
Alexandre Roux ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Young Adults ◽  
Incidence Rates ◽  
Adolescents And Young Adults ◽  
Central Nervous System Tumors ◽  
Crude Rate ◽  
Histological Subtypes ◽  
Nervous System Tumors ◽  
Tumor Identification

Abstract Background Primary central nervous system tumors (PCNST) among adolescents and young adults (AYA, 15–39 y) have rarely been reported. We present a nationwide report of PCNST histologically confirmed in the French AYA population between 2008 and 2013. Methods Patients were identified through the French Brain Tumor Database (FBTDB), a national dataset that includes prospectively all histologically confirmed cases of PCNST in France. Patients aged 15 to 39 years with histologically confirmed PCNST diagnosed between 2008 and 2013 were included. For each of the 143 histological subtypes of PCNST, crude rates, sex, surgery, and age distribution were provided. To enable international comparisons, age-standardized incidence rates were adjusted to the world-standard, European, and USA populations. Results For 6 years, 9661 PCNST (males/females: 4701/4960) were histologically confirmed in the French AYA population. The overall crude rate was 8.15 per 100 000 person-years. Overall, age-standardized incidence rates were (per 100 000 person-years, population of reference: world/Europe/USA): 7.64/8.07/8.21, respectively. Among patients aged 15–24 years, the crude rate was 5.13 per 100 000. Among patients aged 25–39 years, the crude rate was 10.10 per 100 000. Age-standardized incidence rates were reported for each of the 143 histological subtypes. Moreover, for each histological subtype, data were detailed by sex, age, type of surgery (surgical resection or biopsy), and cryopreserved samples. Conclusion These data represent an exhaustive report of all histologically confirmed cases of PCNST with their frequency and distribution in the French AYA population in 2008–2013. For the first time in this age group, complete histological subtypes and rare tumor identification are detailed.

scholarly journals A Comparison of Epidemiological Characteristics of Central Nervous System Tumours in China and Globally from 1990 to 2019

2021 ◽  
Vol 55 (6) ◽  
pp. 460-472
Author(s):  
Bo Zhu ◽  
Xiaomei Wu ◽  
Haozhe Piao ◽  
Shuang Xu ◽  
Bing Yao
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Epidemiological Data ◽  
Incidence Rates ◽  
Older Age ◽  
Age Group ◽  
Central Nervous System Tumours ◽  
Life Years ◽  
Epidemiological Characteristics ◽  
Incident Cases

<b><i>Background:</i></b> Despite their great disease burden, there have been few studies on the epidemiology of central nervous system tumours (CNSTs) in China. We used the latest data updated by GBD to analyse the trends of incidence, mortality, and disability-adjusted life years (DALYs) for CNSTs in China versus globally. <b><i>Methods:</i></b> Epidemiological data on CNSTs were extracted from GBD 2019. We used Joinpoint regression analysis to calculate the magnitude and direction of the trends and the age-period-cohort method to analyse the age, period, and cohort effects of the trend. <b><i>Results:</i></b> From 1990 to 2019, the 106.52% increase in Chinese incident cases was higher than the global increase (94.35%). The 67.32% increase in cancer deaths and 16.03% increase in DALYs were lower than the global increases (cancer death: 76.36%; DALYs: 40.06%). The age-standardized incidence rates (ASIRs) in China were higher than the global ASIRs, and the increase in China was higher than that globally. Although the age-standardized mortality rates and age-standardized DALY rates in China were higher, their increases in China were less than those globally. Both in China and globally, the number and incidence, mortality, and DALYs by age group showed a bimodal distribution (younger than 5 years and older), and the peak in the older age group showed a backwards trend. The proportion of incident cases, cancer deaths, and DALYs also increased in the older age group. In the age-period-cohort model, the local drifts in the older age group were above zero. <b><i>Conclusions:</i></b> The burden of CNSTs is very serious in China, and we should pay attention to the key populations, early diagnosis technology, improvements in medical technology, and ways to reduce medical costs. We believe our results could help policymakers allocate resources efficiently to reduce the burden of CNSTs.

scholarly journals The use of 4-Demethyl-4-cholesteryloxypenclomedine [DM-CHOC-PEN] as Therapy in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies Involving the Central Nervous System (CNS)

2021 ◽  
pp. 31-33
Author(s):  
Morgan LR ◽  
Weiner RS ◽  
Ware ML ◽  
Bhandari M ◽  
Mahmood T ◽  
...  
Keyword(s):  
United States ◽  
Central Nervous System ◽  
Nervous System ◽  
Young Adults ◽  
Young Adult ◽  
The United States ◽  
Adolescents And Young Adults ◽  
Adolescent And Young Adult ◽  
Advanced Malignancies ◽  
The Central Nervous System

In 2020 about 89,000 adolescents and young adults (AYA) (ages 15 to 39) were estimated to be diagnosed with cancer in the United States, 23,890 had CNS and spinal nervous system(SNS) involvement—accounting for one twentieth or five percent of the number cancer diagnoses in the United States. The estimated deaths for this group was18,020 deaths in 2020 (1).

Sign in / Sign up

Export Citation Format

Share Document